- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05724576
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
Study Overview
Detailed Description
Despite state-of-the-art advances in the treatment of acute myocardial infarction (AMI), including early and prompt reperfusion therapy and advanced pharmaceutical therapy, AMI remains the leading cause of death of patients hospitalized for cardiovascular disease. Loss of myocardium after AMI, resulting in reducing LVEF and ultimately pump failure, are essential for unfavorable clinical outcomes and mortality, highlighting that to protect the myocardium from AMI-induced damage is the principal rule for treatment of the AMI patients. The pathological findings have clearly identified that loss of myocardium after AMI results from first ischemic necrosis, followed by ischemia-reperfusion injury, vigorous inflammatory reaction, generation of oxidative stress, and finally, upregulation of immune reaction. Thus, a phenomenon of "propagation of myocardium from injury to irrepressible death" at the moment just after AMI always occurs. These are the reasons why a satisfactory therapy for AMI is still difficult, highlighting the timing remains the Achilles' heel for salving the jeopardized myocardium. These raise the consideration of urgently to develop a new effective and safe treatment for patients.
Abundant data have shown mesenchymal stromal cells (MSC) pleiotropic capacities of anti-inflammation, immunomodulation, and tissue regeneration. Experimental studies have further demonstrated that MSC therapy effectively protected the organs from ischemic/ischemia-reperfusion injury. However, the therapeutic impact of stem cells on the clinical setting of AMI is still universally controversial. When investigators further look at the clinical trials, delayed time to apply the stem cells on AMI patients is universally consistent. Investigators have demonstrated that early intracoronary administration (i.e., at the time interval of 90 minutes after AMI induction) of OmniMSC-AMI significantly protected the left ventricular myocardium and improved LVEF in the mini-pig AMI model. The aforementioned issues and the results of our experimental study may support our hypothesis that immediate intracoronary administration of OmniMSC-AMI into the infarcted-related vessel in first AMI patients who just yet underwent primary PCI will be safe and may offer benefits in improving LVEF and outcome.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Timothy Huang, PhD
- Phone Number: 512 02-26956382
- Email: timothy.huang@twbio-thera.com
Study Locations
-
-
-
Kaohsiung city, Taiwan
- Recruiting
- Kaohsiung Chang Gung Memorial Hospital
-
Contact:
- Hon-Kan Yip, MD
- Email: han.gung@msa.hinet.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patents, with age ≤20 or ≤80 years old.
Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction):
- Chest pain onset.
- 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm.
- TnT-I elevation.
- Into emergency ≤ 6h upon AMI presentation.
- Patients are willing to receive the treatment and sign the informed consent.
Exclusion Criteria:
- Age < 20 or >80 years old.
History of
- Malignancy.
- Sepsis (abnormal WBC count elevation).
- Hematologic disorder.
- AIDS.
- Advanced liver cirrhosis.
- CKD stage 5 with Ccr <15 ml/min.
- AMI occurrence > 6 hours
- Non-first AMI.
- Pregnancy or breastfeeding.
- Prison.
- Cancer treatment within 2 years.
- Expected lifespan < 6 months.
- Non-suitable candidate evaluated by PI.
- Participating in other clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose allogeneic mesenchymal stromal cells
Intracoronary administration 1.5 x 10^7 OmniMSC-AMI in first AMI patients who just underwent primary PCI
|
10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10^7 OmniMSC-AMI, n=5).
|
Experimental: High dose allogeneic mesenchymal stromal cells
Intracoronary administration 3.0 x 10^7 OmniMSC-AMI in first AMI who just underwent primary PCI
|
10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10^7 OmniMSC-AMI, n=5).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 30 days
|
Number of adverse events occurring in given time frame shall be reported to evaluate overall safety.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart function after AMI
Time Frame: 1-7 days
|
Cardiac MRI and 2-D/3-D echo LVEF results after administration
|
1-7 days
|
Heart function after treatment
Time Frame: 6 months
|
Cardiac MRI and 2-D/3-D echo LVEF results after administration
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hon-Kan Yip, MD, Chang Gung Memorial Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202002401A0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety Issues
-
Chulalongkorn UniversityNot yet recruiting
-
IC-MedTech CorporationRecruiting
-
Showa Inan General HospitalRecruiting
-
Asmaa Elwan Mohammed HassanCompleted
-
Hadassah Medical OrganizationGals Bio Ltd.Withdrawn
-
Federico II UniversityCompleted
-
Institute of Nuclear Energy Research, TaiwanCompleted
-
University of JordanCompleted
-
Hospital Universitario La FeSENSAR (Sistema español de notificación en seguridad en anestesia y reanimación)Completed
Clinical Trials on OmniMSC-AMI
-
UConn HealthCompletedGingivitisUnited States
-
Athersys, IncPPD; Angiotech PharmaceuticalsCompleted
-
McMaster UniversityHamilton Health Sciences Corporation; Centre for Evidence-Based ImplementationCompleted
-
Janssen Research & Development, LLCRecruitingAdvanced Solid MalignanciesUnited States, Korea, Republic of, Canada, United Kingdom
-
Hannover Medical SchoolUniversity of Minnesota; CochlearCompleted
-
Athersys, IncNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart Attack | NSTEMIUnited States
-
Mayo ClinicCompleted
-
Massachusetts Institute of TechnologyEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingAmputationUnited States
-
CellProtheraActive, not recruitingAcute Myocardial InfarctionFrance, United Kingdom
-
Rheinhessen-Fachklinik AlzeyJohannes Gutenberg University MainzUnknown